Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Long-term potent antithrombotic therapy reduces atherothrombotic events after PCI

19 Mar 2020

Long-term treatment with more potent antithrombotic therapy lowers spontaneous atherothrombotic events and prevents complications related to stenting of the culprit lesion following acute coronary syndrome (ACS), suggests a recent study.

“In patients undergoing percutaneous coronary intervention [PCI] for ACS, spontaneous events predominate after 30 days, with the later-phase cardiovascular benefit of potent dual antiplatelet therapy driven largely by reducing de novo atherothrombotic ischaemic events,” the researchers said.

Of the patients included in the TRITON-TMI 38* study, which randomized participants to prasugrel or clopidogrel, 12,844 with ACS received at least one stent. Myocardial infarction (MI) and cardiovascular death were categorized as follows: procedural (related to revascularization); definite or probable stent thrombosis (ST); or spontaneous (non-ST or nonprocedural-related). Median follow-up was 14.5 months.

Of the first events that occurred within 30 days, 584 (69.0 percent) were procedural, 126 (14.9 percent) ST-related and 136 (16.1 percent) spontaneous. After 30 days, 22 (4.7 percent) events were procedural, 63 (13.5 percent) ST-related and 383 (81.8 percent) spontaneous.

Treatment with prasugrel significantly reduced the incidence of MI or cardiovascular death for ST-related (1.0 percent vs 2.1 percent; p<0.001) and spontaneous events (3.9 percent vs 4.8 percent; p=0.012), with a directionally consistent numerical reduction in procedural events (4.4 percent vs 5.1 percent; p=0.078). However, prasugrel led to more spontaneous, but not procedural, major bleeding.

“Recent emphasis on reduced duration and/or intensity of antiplatelet therapy following PCI irrespective of indication for PCI may fail to account for the substantial risk of subsequent nontarget lesion events in ACS patients,” the researchers said.

*Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.